HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Reaction

Diethyl Ether → 3-tert-butoxycarbonyl-7-chloro-6-[5-(2,2-dimethyl-propyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine

HRID 911492
Print

Reaction equation

HRID 911492 reaction equation
[CH2:1]([Mg]Cl)[C:2]([CH3:5])([CH3:4])[CH3:3].C(OCC)C.[C:13]([O:17][C:18]([N:20]1[CH2:26][CH2:25][C:24]2[C:27]([S:32][CH2:33][C:34]3[CH:39]=[CH:38][C:37](Br)=[CH:36][N:35]=3)=[C:28]([Cl:31])[CH:29]=[CH:30][C:23]=2[CH2:22][CH2:21]1)=[O:19])([CH3:16])([CH3:15])[CH3:14]>C1COCC1.CCOC(C)=O.[Cl-].[Zn+2].[Cl-].C1C=CC([PH+]([C]2[CH][CH][CH][CH]2)C2C=CC=CC=2)=CC=1.C1C=CC([PH+]([C]2[CH][CH][CH][CH]2)C2C=CC=CC=2)=CC=1.C(Cl)Cl.Cl[Pd]Cl.[Fe]>[C:13]([O:17][C:18]([N:20]1[CH2:26][CH2:25][C:24]2[C:27]([S:32][CH2:33][C:34]3[CH:39]=[CH:38][C:37]([CH2:1][C:2]([CH3:5])([CH3:4])[CH3:3])=[CH:36][N:35]=3)=[C:28]([Cl:31])[CH:29]=[CH:30][C:23]=2[CH2:22][CH2:21]1)=[O:19])([CH3:16])([CH3:14])[CH3:15]
ParticipantsProcedureWorkupSources & evidenceReaction notes

Participants

8

Reactant 3

HCID 3283Diethyl EtherHCID 576562493-tert-butoxycarbonyl-6-(5-bromopyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepineHCID 178418809HCID 178418809, compound

Product 1

HCID 667068963-tert-butoxycarbonyl-7-chloro-6-[5-(2,2-dimethyl-propyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepineYield 24%

Reagents, catalysts & solvents 4

HCID 3007855
Sinkkikloridi
Catalyst
HCID 53485975CID 53485975Catalyst
HCID 8028TetrahydrofuranSolvent2×
HCID 8857Ethyl AcetateSolvent

Procedure

To a stirred solution of 1.0 M neopentyl magnesium chloride in diethyl ether (50 mL, 50 mmol) at −78° C. under nitrogen, add via syringe a solution of 0.5 M zinc chloride in THF (100 mL, 50 mmol). Warm gradually to ambient temperature and transfer via syringe of this solution (25 mL, ˜8.33 mmol) to a stirred solution of 3-tert-butoxycarbonyl-6-(5-bromo-pyridin-2-ylmethylthio)-7-chloro-2,3,4,5-tetrahydro-1H-benzo[d]azepine (300 mg, 0.62 mmol) in THF (2 mL) at ambient temperature. Add dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (50 mg, 0.061 mmol) and heat at 65° C. for 6 h. Cool to ambient temperature, dilute with EtOAc, wash with water, dry over anhydrous MgSO4 and concentrate in vacuo. Purify by chromatography on silica gel eluting with hexane/EtOAc (6:1) to give 3-tert-butoxycarbonyl-7-chloro-6-[5-(2,2-dimethyl-propyl)-pyridin-2-ylmethylthio]-2,3,4,5-tetrahydro-1H-benzo[d]azepine as an oil (69 mg, 24%). MS (APCI+) m/z: 501 (M+H)+. Use a method similar to the General Procedure 1-4 to give the title compound as a white powder. MS (APCI+) m/z: 375 (M+H)+.

Workup

  1. customat ambient temperature
  2. temperatureCool to ambient temperature
  3. washwash with water
  4. dry with materialdry over anhydrous MgSO4
  5. concentrationconcentrate in vacuo
  6. customPurify by chromatography on silica gel eluting with hexane/EtOAc (6:1)

Sources & evidence

ORD record
ord-0e9619f7688a4ef1b83775a6242eb3b2
Source dataset
uspto-grants-2011_09
DOI
10.6084/m9.figshare.5104873.v1
Patent number
US08022062B2

Reaction notes

On this pageParticipantsProcedureWorkupSources & evidenceReaction notes